People

Stephen J. Kron, MD PhD

The Kron laboratory is a diverse and collaborative group of cell biologists, geneticists, biochemists, chemists and computer scientists. Our current basic research and technology efforts include 1) defining roles for chromatin dynamics and cell cycle regulation in DNA damage checkpoint response and cellular senescence, 2) dissecting cross-talk between metabolism and DNA damage response, 3) developing novel molecular assays to interrogate cell signaling in cancer, and 4) implementing novel mass spectrometry approaches to enable quantitative proteomics. We also pursue translational projects directed at 1) discovering inhibitors of cellular response to DNA double strand breaks as an approach to radiosensitization, 2) examining DNA damage and repair in tissues and tumors, and 3) exploiting DNA damage responses to induce anti-tumor immune responses.

Whitehead Institute
Cambridge MA
- Genetics
1995

Stanford University
Stanford CA
PhD - Cell Biology
1990

Stanford University
Stanford CA
MD - Medicine
1990

University of Pennsylvania
Philadelphia PA
MSE - Bioengineering
1983

University of Pennsylvania
Philadelphia PA
BA - Biochemistry
1982

Small-molecule drug repurposing to target DNA damage repair and response pathways.
Brinkman JA, Liu Y, Kron SJ. Small-molecule drug repurposing to target DNA damage repair and response pathways. Semin Cancer Biol. 2020 Feb 27.
PMID: 32113999

Targeted Covalent Inhibition of Telomerase.
Betori RC, Liu Y, Mishra RK, Cohen SB, Kron SJ, Scheidt KA. Targeted Covalent Inhibition of Telomerase. ACS Chem Biol. 2020 03 20; 15(3):706-717.
PMID: 32017522

The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair.
Moreno NS, Liu J, Haas KM, Parker LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C, Robinson PJ, Lelièvre SA, Vidi PA. The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair. Nucleic Acids Res. 2019 11 04; 47(19):10475.
PMID: 31511892

Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer.
Ricco N, Flor A, Wolfgeher D, Efimova EV, Ramamurthy A, Appelbe OK, Brinkman J, Truman AW, Spiotto MT, Kron SJ. Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer. Mol Oncol. 2019 09; 13(9):1927-1943.
PMID: 31225926

Immune profiles in primary squamous cell carcinoma of the head and neck.
Saloura V, Izumchenko E, Zuo Z, Bao R, Korzinkin M, Ozerov I, Zhavoronkov A, Sidransky D, Bedi A, Hoque MO, Koeppen H, Keck MK, Khattri A, London N, Kotlov N, Fatima A, Vougiouklakis T, Nakamura Y, Lingen M, Agrawal N, Savage PA, Kron S, Kline J, Kowanetz M, Seiwert TY. Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncol. 2019 09; 96:77-88.
PMID: 31422218

Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence.
Liu Y, Efimova EV, Ramamurthy A, Kron SJ. Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence. J Cell Sci. 2019 07 01; 132(13).
PMID: 31189537

Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex.
Hernández-Ortega S, Sánchez-Botet A, Quandt E, Masip N, Gasa L, Verde G, Jiménez J, Levin RS, Rutaganira FU, Burlingame AL, Wolfgeher D, Ribeiro MPC, Kron SJ, Shokat KM, Clotet J. Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex. Exp Mol Med. 2019 04 16; 51(4):1-17.
PMID: 30992425

A cmap-enabled gene expression signature-matching approach identifies small-molecule inducers of accelerated cell senescence.
Wu D, Pepowski B, Takahashi S, Kron SJ. A cmap-enabled gene expression signature-matching approach identifies small-molecule inducers of accelerated cell senescence. BMC Genomics. 2019 Apr 15; 20(1):290.
PMID: 30987592

Targeted antibody and cytokine cancer immunotherapies through collagen affinity.
Ishihara J, Ishihara A, Sasaki K, Lee SS, Williford JM, Yasui M, Abe H, Potin L, Hosseinchi P, Fukunaga K, Raczy MM, Gray LT, Mansurov A, Katsumata K, Fukayama M, Kron SJ, Swartz MA, Hubbell JA. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med. 2019 04 10; 11(487).
PMID: 30971453

The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair.
Salvador Moreno N, Liu J, Haas KM, Parker LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C, Robinson PJ, Lelièvre SA, Vidi PA. The nuclear structural protein NuMA is a negative regulator of 53BP1 in DNA double-strand break repair. Nucleic Acids Res. 2019 04 08; 47(6):2703-2715.
PMID: 30812030

View All Publications